Literature DB >> 11037883

Increased phosphorylation of transcription factor Sp1 in scleroderma fibroblasts: association with increased expression of the type I collagen gene.

H Ihn1, K Tamaki.   

Abstract

OBJECTIVE: To determine the potential roles of transcription factors Sp1 and Sp3 in the increased expression of the human alpha2(I) collagen gene in scleroderma fibroblasts.
METHODS: Dermal fibroblasts from 7 patients with diffuse systemic sclerosis (SSc; scleroderma) of recent onset and from 7 healthy individuals were studied. The levels of expression of alpha2(I) procollagen, Sp1, and Sp3 messenger RNA (mRNA), with or without stimulation by transforming growth factor beta (TGFbeta) or oncostatin M (OSM), were evaluated by Northern blot analysis, and the respective protein levels were determined by immunoblotting. The DNA binding activity of nuclear proteins recognizing the cis-acting elements in the human alpha2(I) collagen promoter was examined by gel mobility shift assays. The levels of Sp1 phosphorylation were investigated by immunoprecipitation using an antiphosphoserine-specific antibody.
RESULTS: SSc fibroblasts showed basal alpha2(I) collagen mRNA levels that were approximately 3 times higher than those in normal fibroblasts. TGFbeta or OSM increased human alpha2(I) collagen mRNA expression in normal dermal fibroblasts, but these cytokines failed to increase alpha2(I) collagen mRNA levels in SSc fibroblasts. There were no significant differences in the levels of expression of Sp1 or Sp3 between SSc and normal fibroblasts. However, increased Sp1 phosphorylation was detected in SSc fibroblasts compared with normal fibroblasts. Mithramycin, a specific inhibitor of Sp1 binding, abolished the increased expression of the alpha2(I) collagen gene in SSc fibroblasts, in a dose-dependent manner.
CONCLUSION: These results demonstrate the involvement of Sp1 in the up-regulation of expression of the alpha2(I) collagen gene in SSc fibroblasts.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11037883     DOI: 10.1002/1529-0131(200010)43:10<2240::AID-ANR11>3.0.CO;2-2

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  13 in total

Review 1.  The genetics of systemic sclerosis.

Authors:  Randall W Johnson; Monty B Tew; Frank C Arnett
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

Review 2.  Matrix remodeling in systemic sclerosis.

Authors:  Andrew Leask
Journal:  Semin Immunopathol       Date:  2015-07-04       Impact factor: 9.623

Review 3.  Scleroderma, fibroblasts, signaling, and excessive extracellular matrix.

Authors:  Hironobu Ihn
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

4.  The p65 subunit of NF-κB inhibits COL1A1 gene transcription in human dermal and scleroderma fibroblasts through its recruitment on promoter by protein interaction with transcriptional activators (c-Krox, Sp1, and Sp3).

Authors:  Gallic Beauchef; Nicolas Bigot; Magdalini Kypriotou; Emmanuelle Renard; Benoît Porée; Russell Widom; Anne Dompmartin-Blanchere; Thierry Oddos; François-Xavier Maquart; Magali Demoor; Karim Boumediene; Philippe Galera
Journal:  J Biol Chem       Date:  2011-12-02       Impact factor: 5.157

5.  Inhibition of collagen gene expression in systemic sclerosis dermal fibroblasts by mithramycin.

Authors:  N Sandorfi; N Louneva; E Hitraya; G Hajnoczky; B Saitta; S A Jimenez
Journal:  Ann Rheum Dis       Date:  2005-05-18       Impact factor: 19.103

6.  Transcriptional regulation of matrix metalloproteinase-1 and collagen 1A2 explains the anti-fibrotic effect exerted by proteasome inhibition in human dermal fibroblasts.

Authors:  Laurence Goffin; Queralt Seguin-Estévez; Montserrat Alvarez; Walter Reith; Carlo Chizzolini
Journal:  Arthritis Res Ther       Date:  2010-04-29       Impact factor: 5.156

7.  Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts.

Authors:  Yoshihide Asano; Hironobu Ihn; Kenichi Yamane; Masahide Kubo; Kunihiko Tamaki
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

8.  Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin.

Authors:  Masahide Kubo; Joanna Czuwara-Ladykowska; Omar Moussa; Margaret Markiewicz; Edwin Smith; Richard M Silver; Stefania Jablonska; Maria Blaszczyk; Dennis K Watson; Maria Trojanowska
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

Review 9.  Antifibrotic therapy in scleroderma: extracellular or intracellular targeting of activated fibroblasts?

Authors:  John Varga
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

10.  Post-translational control of sp-family transcription factors.

Authors:  J S Waby; C D Bingle; B M Corfe
Journal:  Curr Genomics       Date:  2008       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.